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Summary
Study Question:	What	is	the	recommended	assessment	and	management	of	women	
with	polycystic	ovary	syndrome	(PCOS),	based	on	the	best	available	evidence,	clinical	
expertise,	and	consumer	preference?
Summary Answer:	International	evidence-	based	guidelines	including	166	recommenda-
tions	and	practice	points,	addressed	prioritized	questions	to	promote	consistent,	evidence-	
based	care	and	improve	the	experience	and	health	outcomes	of	women	with	PCOS.
What is Known Already:	Previous	guidelines	either	lacked	rigorous	evidence-	based	
processes,	did	not	engage	consumer	and	international	multidisciplinary	perspectives,	
or	 were	 outdated.	 Diagnosis	 of	 PCOS	 remains	 controversial	 and	 assessment	 and	
management	 are	 inconsistent.	 The	 needs	 of	 women	 with	 PCOS	 are	 not	 being	
	adequately	met	and	evidence	practice	gaps	persist.
Study Design, Size, Duration:	International	evidence-	based	guideline	development	en-
gaged	professional	societies	and	consumer	organizations	with	multidisciplinary	experts	
and	 women	 with	 PCOS	 directly	 involved	 at	 all	 stages.	 Appraisal	 of	 Guidelines	 for	
Research	and	Evaluation	(AGREE)	II-	compliant	processes	were	followed,	with	extensive	
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1  | WHAT DOES THIS ME AN FOR 
ADOLESCENTS AND WOMEN WITH PCOS?
This	 guideline	 aims	 to	 optimize	 evidence-	based,	 consistent	 care	
that	meets	the	needs	and	 improves	the	quality	of	 life	of	women	
with	 PCOS.	 The	 guideline	 and	 translation	 program	were	 devel-
oped	with	full	consumer	participation	at	all	stages,	targeting	areas	
and	 outcomes	 of	 priority	 for	 women	 with	 PCOS.	 The	 aim	 is	 to	
support	 women	 and	 their	 health	 care	 providers	 to	 optimize	 di-
agnosis,	 assessment	and	management	of	PCOS.	There	 is	an	em-
phasis	on	partnership	 in	care	and	empowerment	of	women	with	
PCOS.	 Personal	 characteristics,	 preferences,	 culture	 and	 values	
are	 considered.	 With	 effective	 translation,	 the	 guideline	 and	
health	professional	and	consumer	resources	will	address	gaps	and	
priorities	 identified	by	women	with	PCOS	and	will	promote	vital	
future	research.
evidence	synthesis.	The	Grading	of	Recommendations,	Assessment,	Development,	and	
Evaluation	(GRADE)	framework	was	applied	across	evidence	quality,	feasibility,	accept-
ability,	cost,	implementation	and	ultimately	recommendation	strength.
Participants/Materials, Setting, Methods:	Governance	included	a	six	continent	inter-
national	advisory	and	a	project	board,	five	guideline	development	groups	(GDGs),	and	
consumer	and	translation	committees.	Extensive	health	professional	and	consumer	en-
gagement	 informed	 guideline	 scope	 and	 priorities.	 Engaged	 international	 society-	
nominated	 panels	 included	 pediatrics,	 endocrinology,	 gynecology,	 primary	 care,	
reproductive	 endocrinology,	 obstetrics,	 psychiatry,	 psychology,	 dietetics,	 exercise	
physiology,	 public	 health	 and	 other	 experts,	 alongside	 consumers,	 project	manage-
ment,	evidence	synthesis,	and	translation	experts.	Thirty-	seven	societies	and	organiza-
tions	covering	71	countries	engaged	in	the	process.	Twenty	face-	to-	face	meetings	over	
15	months	addressed	60	prioritized	clinical	questions	involving	40	systematic	and	20	
narrative	 reviews.	 Evidence-	based	 recommendations	were	developed	 and	 approved	
via	consensus	voting	within	the	five	guideline	panels,	modified	based	on	international	
feedback	and	peer	review,	with	final	recommendations	approved	across	all	panels.
Main Results and the Role of Chance:	The	evidence	in	the	assessment	and	management	
of	PCOS	 is	 generally	of	 low	 to	moderate	quality.	The	guideline	provides	31	evidence	
based	recommendations,	59	clinical	consensus	recommendations	and	76	clinical	practice	
points	all	related	to	assessment	and	management	of	PCOS.	Key	changes	in	this	guideline	
include:	(a)	considerable	refinement	of	individual	diagnostic	criteria	with	a	focus	on	im-
proving	accuracy	of	diagnosis;	(b)	reducing	unnecessary	testing;	(c)	increasing	focus	on	
education,	lifestyle	modification,	emotional	wellbeing	and	quality	of	life;	and	(d)	empha-
sizing	evidence	based	medical	therapy	and	cheaper	and	safer	fertility	management.
Limitations, Reasons for Caution:	Overall	evidence	is	generally	low	to	moderate	qual-
ity,	requiring	significantly	greater	research	in	this	neglected,	yet	common	condition,	
especially	around	refining	specific	diagnostic	features	in	PCOS.	Regional	health	sys-
tem	variation	is	acknowledged	and	a	process	for	guideline	and	translation	resource	
adaptation	is	provided.
Wider Implications of the Findings:	The	 international	guideline	for	the	assessment	and	
management	of	PCOS	provides	clinicians	with	clear	advice	on	best	practice	based	on	the	
best	available	evidence,	expert	multidisciplinary	input	and	consumer	preferences.	Research	
recommendations	have	been	generated	and	a	comprehensive	multifaceted	dissemination	
and	translation	program	supports	the	guideline	with	an	integrated	evaluation	program.
K E Y W O R D S
assessment,	evidence-based,	GRADE,	guideline,	management,	polycystic	ovary	syndrome
     |  3TEEDE ET al.
2  | INTRODUC TION
Polycystic	 ovary	 syndrome	 (PCOS)	 is	 the	 most	 common	 endo-
crinopathy	affecting	 reproductive	aged	women,	with	a	prevalence	
of	 between	 8%	 to	 13%	depending	 on	 the	 population	 studied	 and	
definitions	used.1,2	PCOS	 is	 complex	with	 reproductive,	metabolic	
and	psychological	features.1,2	Clinical	practice	in	the	assessment	and	
management	 of	 PCOS	 is	 inconsistent,	 with	 key	 evidence	 practice	
gaps,	whilst	women	 internationally	 have	 highlighted	 delayed	 diag-
nosis	and	dissatisfaction	with	care.3-5	Current	guidelines	either	are	
limited	in	breadth,	do	not	follow	rigorous	best	practice	in	develop-
ment,	 have	 not	 involved	 consumers,	 or	 are	 outdated,6-10	 resulting	
in	inconsistent	guidance	for	clinicians	and	women	alike.	To	address	
these	identified	gaps,	here	we	summarize	the	development	process	
and	 recommendations	 from	 the	 first	 international	 evidence-	based	
guideline	 for	 the	 assessment	 and	management	 of	 PCOS,	 bringing	
extensive	 consumer	 engagement	 and	 international	 collaboration	
with	 leading	 societies	 and	organizations,	multidisciplinary	experts,	
and	primary	care	representatives.	In	this	process,	the	guideline	de-
velopment	groups	unanimously	supported	the	Rotterdam	diagnostic	
criteria	for	adult	women.
This	 comprehensive	 evidence-	based	 guideline	builds	 on	prior	
high	quality	guidelines	and	culminates	 from	a	 rigorous,	AGREEII-	
compliant,	 evidence-	based	 guideline	 development	 process.	 It	
provides	 a	 single	 source	 of	 international	 evidence-	based	 recom-
mendations	to	guide	clinical	practice	with	the	opportunity	for	ad-
aptation	 in	 relevant	 health	 systems.	 Together	 with	 an	 extensive	
translation	 program,	 the	 aim	 is	 to	 reduce	worldwide	 variation	 in	
care	and	promote	high	quality	service	provision	to	improve	health	
outcomes	and	quality	of	life	in	women	with	PCOS.	The	guidelines	
are	supported	by	a	multifaceted	international	translation	program	
with	 co-	designed	 resources	 to	 upskill	 health	 professionals	 and	
empower	women	with	 PCOS,	with	 an	 integrated	 comprehensive	
evaluation	program.
3  | MATERIAL S AND METHODS
Best	practice	evidence-	based	guideline	development	methods	were	
applied	and	are	detailed	in	the	full	guideline	and	the	technical	re-
ports	and	outlined	in	Figure	1	and	available	at	https://www.monash.
edu/medicine/sphpm/mchri/pcos.11	The	process	aligns	with	all	el-
ements	of	the	Appraisal	of	Guidelines	for	Research	and	Evaluation	
(AGREE)	II	tool	for	quality	guideline	assessment.12	This	involved	ex-
tensive	evidence	synthesis	and	the	Grading	of	Recommendations,	
Assessment,	 Development,	 and	 Evaluation	 (GRADE)	 framework	
covering	 evidence	 quality,	 feasibility,	 acceptability,	 cost,	 imple-
mentation,	 and	 ultimately	 recommendation	 strength.13	 Evidence	
synthesis	methods	are	outlined	in	the	full	guideline	and	followed	
best	practice.12-15	Categories	 include	evidence-	based	or	 consen-
sus	recommendations	with	accompanying	clinical	practice	points	 
(Table	1).
Terms	include	“should,”	“could,”	and	“should	not,”	are	informed	
by	the	nature	of	the	recommendation	(evidence	or	consensus),	the	
GRADE	framework	and	quality	of	the	evidence	and	are	indepen-
dent	descriptors	reflecting	the	judgement	of	the	multidisciplinary	
GDG	 including	 consumers.	 They	 refer	 to	 overall	 interpretation	
and	practical	application	of	the	recommendation,	balancing	ben-
efits	 and	 harms.	 “Should”	 is	 used	where	 benefits	 of	 the	 recom-
mendation	exceed	harms,	and	where	the	recommendation	can	be	
trusted	to	guide	practice.	“Could”	is	used	where	either	the	quality	
of	evidence	was	limited	or	the	available	studies	demonstrate	little	
F IGURE  1 The	Steps	in	Developing	an	Evidence-	based	Guideline.	Reproduced	with	Permission	from	Misso	and	Teede11
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clear	advantage	of	one	approach	over	another,	or	the	balance	of	
benefits	to	harm	was	unclear.	“Should	not”	is	used	where	there	is	
either	a	lack	of	appropriate	evidence,	or	the	harms	may	outweigh	
the	benefits.
The	 GRADE	 of	 the	 recommendation	 is	 determined	 by	 the	
GDG	based	on	comprehensive	structured	consideration	of	all	el-
ements	of	 the	GRADE	 framework,4	 including	desirable	effects,	
undesirable	 effects,	 balance	 of	 effects,	 resource	 requirements	
and	cost	effectiveness,	equity,	acceptability	and	 feasibility	and	
includes:
*	Conditional	recommendation	against	the	option;
**	 Conditional	 recommendation	 for	 either	 the	 option	 or	 the	
comparison;
***	Conditional	recommendation	for	the	option;
****	Strong	recommendation	for	the	option.
Quality	of	the	evidence	is	categorized	according	to:	the	num-
ber	 and	 design	 of	 studies	 addressing	 the	 outcome;	 judgments	
about	the	quality	of	the	studies	and/or	synthesized	evidence,	such	
as	 risk	 of	 bias,	 inconsistency,	 indirectness,	 imprecision,	 and	 any	
other	 considerations	 that	 may	 influence	 the	 quality	 of	 the	 evi-
dence;	key	statistical	data;	and	classification	of	the	importance	of	
the	outcomes	(Table	2).	The	quality	of	evidence	reflects	the	extent	
of	confidence	in	an	estimate	of	the	effect	to	support	a	particular	
recommendation4	and	was	 largely	determined	by	the	expert	evi-
dence	synthesis	team.
Grading	 of	 Recommendations,	 Assessment,	 Development,	 and	
Evaluation	acknowledges	that	evidence	quality	is	a	continuum;	any	dis-
crete	categorization	involves	a	degree	of	arbitrariness.	Nevertheless,	
advantages	of	simplicity,	transparency,	and	vividness	outweigh	these	
limitations.4
4  | RESULTS
The	recommendation	 table	 (Table	3)	applies	 the	category,	descrip-
tive	terms,	GRADE	of	the	recommendations	and	the	quality	of	the	
evidence.	 The	 full	 guideline	 is	 available	 at	 https://www.monash.
edu/medicine/sphpm/mchri/pcos.	The	 full	version	of	 the	guideline	
outlines	 the	 clinical	 need	 for	 the	 question,	 the	 clinical	 question,	
the	 evidence	 summary,	 the	 recommendation	 and	 practice	 points	
and	 a	 summary	 of	 the	 justification	 developed	 by	 the	GDGs	 using	
the	 GRADE	 framework,	 refined	 by	 extensive	 international	 peer	
	review.	The	comprehensive	evidence	reviews,	profiles	and	GRADE	
frameworks	 supporting	 each	 recommendation,	 can	 be	 found	 
at	 https://www.monash.edu/medicine/sphpm/mchri/pcos	 in	 the	
Supplementary	 Technical	 Reports.	 The	 peer	 review	 feedback,	 
administrative	 report	 on	 guideline	 development	 and	 disclosure	 of	
interest	 process	 and	 declarations	 can	 be	 found	 at	 https://www.
monash.edu/medicine/sphpm/mchri/pcos.	 Here	 we	 present	 the	
clinical	 topic	 area	 recommendations	 and	 practice	 points	 (Table	3).	
This	summary,	the	full	guideline	and	technical	reports	are	supported	
by	 a	 comprehensive	 co-	designed	 translation	 program	 to	 optimize	
dissemination	and	impact	with	resources	freely	available	at	https://
www.monash.edu/medicine/sphpm/mchri/pcos.
5  | DISCUSSION
The	International	Guideline	for	the	Assessment	and	Management	of	
PCOS	and	the	related	translation	program	aims	to	provide	clinicians	
with	a	quality,	 reliable	source	of	 international	evidence-	based	rec-
ommendations	to	guide	consistent	clinical	practice	and	to	empower	
women	 with	 evidence-	based	 information.	 All	 recommendations	
were	formulated	after	an	assessment	of	the	best	available	evidence,	
TABLE  2 Quality	(certainty)	of	evidence	categories	(adapted	from	GRADE)13
High ⊕⊕⊕⊕ Very	confident	that	the	true	effect	lies	close	to	that	of	the	estimate	of	the	effect.
Moderate ⊕⊕⊕○ Moderate	confidence	in	the	effect	estimate:	the	true	effect	is	likely	to	be	close	to	the	estimate	of	the	
effect,	but	there	is	a	possibility	that	it	is	substantially	different.
Low ⊕⊕○○ Limited	confidence	in	the	effect	estimate:	the	true	effect	may	be	substantially	different	from	the	
estimate	of	the	effect.
Very	Low ⊕○○○ Very	little	confidence	in	the	effect	estimate:	the	true	effect	is	likely	to	be	substantially	different	from	
the	estimate	of	effect.
GRADE,	Grading	of	Recommendations,	Assessment,	Development,	and	Evaluation.
TABLE  1 Categories	of	recommendations	in	the	polycystic	ovary	syndrome	(PCOS)	guideline
EBR Evidence-	based	recommendations	are	made	where	evidence	is	sufficient	to	inform	a	recommendation	made	by	the	guideline	
development	group.
CCR Clinical	consensus	recommendations	are	made	in	the	absence	of	adequate	evidence	on	PCOS.	These	are	informed	by	evidence	in	
other	populations	and	are	made	by	the	guideline	development	group,	using	rigorous	and	transparent	processes.
CPP Clinical	practice	points	are	made	where	evidence	was	not	sought	and	are	made	where	important	clinical	issues	arose	from	discussion	
of	evidence-	based	or	clinical	consensus	recommendations.
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TABLE  3 Recommendations	and	practice	points
Category Recommendation
GRADE and 
quality
1.	Screening,	diagnostic	assessment,	risk	assessment,	and	life-	stage
Irregular	cycles	and	ovulatory	dysfunction
CCR Irregular	menstrual	cycles	are	defined	acs:
•	 Normal	in	the	first	year	post	menarche	as	part	of	the	pubertal	transition
•	 1	to	<3	years	post	menarche:	<21	or	>45	days.
•	 3	years	post	menarche	to	perimenopause:	<21	or	>35	d	or	<8	cycles	per	year.
•	 1	year	post	menarche	>90	days	for	any	one	cycle.
•	 Primary	amenorrhea	by	age	15	or	>3	years	post	thelarche	(breast	development).
When	irregular	menstrual	cycles	are	present	a	diagnosis	of	PCOS	should	be	considered	and	assessed	 
according	to	the	guidelines
****
CCR In	an	adolescent	with	irregular	menstrual	cycles,	the	value	and	optimal	timing	of	assessment	and	diagnosis	of	
PCOS	should	be	discussed	with	the	patient,	taking	into	account	diagnostic	challenges	at	this	life	stage	and	
psychosocial	and	cultural	factors
****
CPP For	adolescents	who	have	features	of	PCOS	but	do	not	meet	diagnostic	criteria,	an	“increased	risk”	could	be	
considered	and	reassessment	advised	at	or	before	full	reproductive	maturity,	8	years	post	menarche.	This	
includes	those	with	PCOS	features	before	combined	oral	contraceptive	pill	(COCP)	commencement,	those	 
with	persisting	features	and	those	with	significant	weight	gain	in	adolescence.
CPP Ovulatory	dysfunction	can	still	occur	with	regular	cycles	and	if	anovulation	needs	to	be	confirmed	serum	
progesterone	levels	can	be	measured
–
Biochemical	hyperandrogenism
EBR Calculated	free	testosterone,	free	androgen	index,	or	calculated	bioavailable	testosterone	should	be	used	to	
assess	biochemical	hyperandrogenism	in	the	diagnosis	of	PCOS
****
⊕⊕○○
EBR High	quality	assays	such	as	liquid	chromatography–mass	spectrometry	(LCMS)	and	extraction/chromatography	
immunoassays,	should	be	used	for	the	most	accurate	assessment	of	total	or	free	testosterone	in	PCOS
***
⊕⊕○○
EBR Androstenedione	and	dehydroepiandrosterone	sulfate	(DHEAS)	could	be	considered	if	total	or	free	 
testosterone	are	not	elevated;	however,	these	provide	limited	additional	information	in	the	diagnosis	of	PCOS
***
⊕⊕○○
CCR Direct	free	testosterone	assays,	such	as	radiometric	or	enzyme-	linked	assays,	preferably	should	not	be	used	in	
assessment	of	biochemical	hyperandrogenism	in	PCOS,	as	they	demonstrate	poor	sensitivity,	accuracy	and	
precision
CPP Reliable	assessment	of	biochemical	hyperandrogenism	is	not	possible	in	women	on	hormonal	contraception,	due	
to	effects	on	sex	hormone-	binding	globulin	and	altered	gonadotrophin-	dependent	androgen	production
–
CPP Where	assessment	of	biochemical	hyperandrogenism	is	important	in	women	on	hormonal	contraception,	drug	
withdrawal	is	recommended	for	three	months	or	longer	before	measurement,	and	contraception	management	
with	a	non-	hormonal	alternative	is	needed	during	this	time
–
CPP Assessment	of	biochemical	hyperandrogenism	is	most	useful	in	establishing	the	diagnosis	of	PCOS	and/or	
phenotype	where	clinical	signs	of	hyperandrogenism	(in	particular	hirsutism)	are	unclear	or	absent
–
CPP Interpretation	of	androgen	levels	needs	to	be	guided	by	the	reference	ranges	of	the	laboratory	used,	 
acknowledging	that	ranges	for	different	methods	and	laboratories	vary	widely.	Normal	values	are	ideally	 
based	on	levels	from	a	well	phenotyped	healthy	control	population	or	by	cluster	analysis	of	a	large	general	
population	considering	age	and	pubertal	specific	stages
–
CPP Where	androgen	levels	are	markedly	above	laboratory	reference	ranges,	other	causes	of	biochemical	 
hyperandrogenism	need	to	be	considered.	History	of	symptom	onset	and	progression	is	critical	in	 
assessing	for	neoplasia,	however,	some	androgen-	secreting	neoplasms	may	only	induce	mild	to	moderate	
increases	in	biochemical	hyperandrogenism
–
Clinical	hyperandrogenism
CCR A	comprehensive	history	and	physical	examination	should	be	completed	for	symptoms	and	signs	of	clinical	
hyperandrogenism,	including	acne,	alopecia,	and	hirsutism	and,	in	adolescents,	severe	acne	and	hirsutism
****
CCR Health	professionals	should	be	aware	of	the	potential	negative	psychosocial	impact	of	clinical	 
hyperandrogenism.	Reported	unwanted	excess	hair	growth	and/or	alopecia	should	be	considered	important,	
regardless	of	apparent	clinical	severity
****
CCR Standardized	visual	scales	are	preferred	when	assessing	hirsutism,	such	as	the	modified	Ferriman	Gallwey	score	
(mFG)	with	a	level	≥4-	6	indicating	hirsutism,	depending	on	ethnicity,	acknowledging	that	self-	treatment	is	
common	and	can	limit	clinical	assessment.	(See	recommendations	on	ethnic	variation)
****
(Continues)
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Category Recommendation
GRADE and 
quality
CCR The	Ludwig	visual	score	is	preferred	for	assessing	the	degree	and	distribution	of	alopecia ****
CPP There	are	no	universally	accepted	visual	assessments	for	evaluating	acne
CPP The	prevalence	of	hirsutism	is	the	same	across	ethnicities,	yet	the	mFG	cut-	off	scores	for	defining	hirsutism	 
and	the	severity	of	hirsutism	varies	by	ethnicity
–
CPP As	ethnic	variation	in	vellus	hair	density	is	notable,	over-	estimation	of	hirsutism	may	occur	if	vellus	hair	is	
confused	with	terminal	hair;	only	terminal	hairs	need	to	be	considered	in	pathological	hirsutism,	with	terminal	
hairs	clinically	growing	>5	mm	in	length	if	untreated,	varying	in	shape	and	texture	and	generally	being	
pigmented
–
Ultrasound	and	polycystic	ovarian	morphology	(PCOM)
CCR Ultrasound	should	not	be	used	for	the	diagnosis	of	PCOS	in	those	with	a	gynecological	age	of	<8	years	(<8	years	
after	menarche),	due	to	the	high	incidence	of	multi-	follicular	ovaries	in	this	life	stage
****
CCR The	threshold	for	PCOM	should	be	revised	regularly	with	advancing	ultrasound	technology,	and	age-	specific	 
cut	off	values	for	PCOM	should	be	defined
****
CCR The	transvaginal	ultrasound	approach	is	preferred	in	the	diagnosis	of	PCOS,	if	sexually	active	and	if	acceptable	
to	the	individual	being	assessed
****
CCR Using	endovaginal	ultrasound	transducers	with	a	frequency	bandwidth	that	includes	8	MHz,	the	threshold	 
for	PCOM	on	either	ovary,	a	follicle	number	per	ovary	of	≥20	and/or	an	ovarian	volume	≥10	ml	on	either	ovary,	
ensuring	no	corpora	lutea,	cysts	or	dominant	follicles	are	present
***
CPP If	using	older	technology,	the	threshold	for	PCOM	could	be	an	ovarian	volume	≥10	ml	on	either	ovary –
CPP In	patients	with	irregular	menstrual	cycles	and	hyperandrogenism,	an	ovarian	ultrasound	is	not	necessary	for	
PCOS	diagnosis;	however,	ultrasound	will	identify	the	complete	PCOS	phenotype
–
CPP In	transabdominal	ultrasound	reporting	is	best	focused	on	ovarian	volume	with	a	threshold	of	≥10	ml,	given	the	
difficulty	of	reliably	assessing	follicle	number	with	this	approach
–
CPP Clear	protocols	are	recommended	for	reporting	follicle	number	per	ovary	and	ovarian	volume	on	ultrasound.	
Recommended	minimum	reporting	standards	include:	
•	 Last	menstrual	period.
•	 Transducer	bandwidth	frequency.
•	 Approach/route	assessed.
•	 Total	follicle	number	per	ovary	measuring	2-9	mm.
•	 Three	dimensions	and	volume	of	each	ovary.
•	 Reporting	of	endometrial	thickness	and	appearance	is	referred;	three-layer	endometrial	assessment	may	
be	useful	to	screen	for	endometrial	pathology.
•	 Other	ovarian	and	uterine	pathology,	as	well	as	ovarian	cysts,	corpus	luteum,	dominant	follicles	≥10	mm.
–
CPP There	is	a	need	for	training	in	careful	and	meticulous	follicle	counting	per	ovary,	to	improve	reporting –
Antimüllerian	hormone	(AMH)
EBR Serum	AMH	levels	should	not	yet	be	used	as	an	alternative	for	the	detection	of	PCOM	or	as	a	single	test	 
for	the	diagnosis	of	PCOS
***
⊕⊕○○
CPP There	is	emerging	evidence	that	with	improved	standardization	of	assays	and	established	cut	off	levels	or	
thresholds	based	on	large	scale	validation	in	populations	of	different	ages	and	ethnicities,	AMH	assays	 
will	be	more	accurate	in	the	detection	of	PCOM
–
Ethnic	variation
CCR Health	professionals	should	consider	ethnic	variation	in	the	presentation	and	manifestations	of	PCOS,	including:	
•	 A	relatively	mild	phenotype	in	Caucasians.
•	 Higher	body	mass	index	(BMI)	in	Caucasian	women,	especially	in	North	America	and	Australia.
•	 More	severe	hirsutism	in	Middle	Eastern,	Hispanic,	and	Mediterranean	women.
•	 Increased	central	adiposity,	insulin	resistance,	diabetes,	metabolic	risks,	and	acanthosis	nigricans	in	South	
East	Asians	and	Indigenous	Australians.
•	 Lower	BMI	and	milder	hirsutism	in	East	Asians.
•	 Higher	BMI	and	metabolic	features	in	Africans.
****
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Menopause	life	stage
CCR Postmenopausal	persistence	of	PCOS	could	be	considered	likely	with	continuing	evidence	of	hyperandrogenism ***
CCR A	diagnosis	of	PCOS	postmenopause	could	be	considered	if	there	is	a	past	diagnosis	of	PCOS,	a	long-	term	
history	of	irregular	menstrual	cycles	and	hyperandrogenism	and/or	PCOM,	during	the	reproductive	years
***
CPP Postmenopausal	women	presenting	with	new-	onset,	severe	or	worsening	hyperandrogenism	including	
hirsutism,	require	investigation	to	rule	out	androgen-	secreting	tumors	and	ovarian	hyperthecosis
–
Cardiovascular	disease	risk	(CVD)
CCR All	those	with	PCOS	should	be	offered	regular	monitoring	for	weight	changes	and	excess	weight,	in	consultation	
with	and	where	acceptable	to	the	individual	woman.	Monitoring	could	be	at	each	visit	or	at	a	minimum	6-	12	
monthly,	with	frequency	planned	and	agreed	between	the	health	professional	and	the	individual
****
CCR Weight,	height,	and	ideally	waist	circumference	should	be	measured	and	BMI	calculated	with	the	following	
considered:	
•	 BMI	categories	and	waist	circumference	should	follow	World	Health	Organization	guidelines,	also	noting	
ethnic	and	adolescent	ranges.
•	 Consideration	should	be	given	for	Asian	and	high-risk	ethnic	groups	including	recommended	monitoring	
of	waist	circumference.
****
CCR All	women	with	PCOS	should	be	assessed	for	cardiovascular	risk	factors	and	global	CVD	risk ****
CCR If	screening	reveals	CVD	risk	factors	including	obesity,	cigarette	smoking,	dyslipidemia,	hypertension,	impaired	
glucose	tolerance,	and	lack	of	physical	activity,	women	with	PCOS	should	be	considered	at	increased	risk	of	
CVD
****
CCR Overweight	and	obese	women	with	PCOS,	regardless	of	age,	should	have	a	fasting	lipid	profile	(cholesterol,	low	
density	lipoprotein	cholesterol,	high	density	lipoprotein	cholesterol	and	triglyceride	level	at	diagnosis).	
Thereafter,	frequency	of	measurement	should	be	based	on	the	presence	of	hyperlipidemia	and	global	CVD	risk
****
CCR All	women	with	PCOS	should	have	blood	pressure	measured	annually,	or	more	frequently	based	on	global	CVD	risk ****
CPP Health	professionals	need	to	be	aware	that	CVD	risk	in	women	with	PCOS	remains	unclear	pending	high	quality	
studies,	however	prevalence	of	CVD	risk	factors	is	increased,	warranting	consideration	of	screening
–
CPP Consideration	needs	to	be	given	to	the	significant	differences	in	CVD	risk	across	ethnicities	(See	Ethnic	
variation)	when	determining	frequency	of	risk	assessment
–
Gestational	diabetes,	impaired	glucose	tolerance	and	type	2	diabetes
CCR Health	professionals	and	women	with	PCOS	should	be	aware	that,	regardless	of	age,	the	prevalence	of	
gestational	diabetes,	impaired	glucose	tolerance	and	type	2	diabetes	(5-	fold	in	Asia,	4-	fold	in	the	Americas,	and	
3-	fold	in	Europe)	are	significantly	increased	in	PCOS,	with	risk	independent	of,	yet	exacerbated	by,	obesity
****
CCR Glycemic	status	should	be	assessed	at	baseline	in	all	women	with	PCOS.	Thereafter,	assessment	should	be	every	
one	to	three	years,	influenced	by	the	presence	of	other	diabetes	risk	factors
****
CCR An	oral	glucose	tolerance	test	(OGTT),	fasting	plasma	glucose	or	HbA1c	should	be	performed	to	assess	glycemic	
status.	In	high-	risk	women	with	PCOS	(including	a	BMI	>25	kg/m2	or	in	Asians	>23	kg/m2,	history	of	impaired	
fasting	glucose,	impaired	glucose	tolerance	or	gestational	diabetes,	family	history	of	diabetes	mellitus	type	2,	
hypertension	or	high-	risk	ethnicity),	an	OGTT	is	recommended
****
CCR A	75-	g	OGTT	should	be	offered	in	all	women	with	PCOS	preconception	when	planning	pregnancy	or	seeking	
fertility	treatment,	given	the	high	risk	of	hyperglycemia	and	the	associated	comorbidities	in	pregnancy.	If	not	
performed	preconception,	an	OGTT	should	be	offered	at	<20	weeks	gestation,	and	all	women	with	PCOS	
should	be	offered	the	test	at	24-	28	weeks	gestation
****
Obstructive	sleep	apnea	(OSA)
CCR Screening	should	only	be	considered	for	OSA	in	PCOS	to	identify	and	alleviate	related	symptoms,	such	as	
snoring,	waking	unrefreshed	from	sleep,	daytime	sleepiness,	and	the	potential	for	fatigue	to	contribute	to	
mood	disorders.	Screening	should	not	be	considered	with	the	intention	of	improving	cardiometabolic	risk,	 
with	inadequate	evidence	for	metabolic	benefits	of	OSA	treatment	in	PCOS	and	in	general	populations
****
CCR A	simple	screening	questionnaire,	preferably	the	Berlin	tool,	could	be	applied	and	if	positive,	referral	to	a	
specialist	considered
***
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CPP A	positive	screen	raises	the	likelihood	of	OSA,	however	it	does	not	quantify	symptom	burden	and	alone	does	
not	justify	treatment.	If	women	with	PCOS	have	OSA	symptoms	and	a	positive	screen,	consideration	can	be	
given	to	referral	to	a	specialist	center	for	further	evaluation
–
Endometrial	cancer
CCR Health	professionals	and	women	with	PCOS	should	be	aware	of	a	2-	to	6-	fold	increased	risk	of	endometrial	cancer,	
which	often	presents	before	menopause;	however	absolute	risk	of	endometrial	cancer	remains	relatively	low
***
CPP Health	professionals	require	a	low	threshold	for	investigation	of	endometrial	cancer	in	women	with	PCOS	or	a	
history	of	PCOS,	with	investigation	by	transvaginal	ultrasound	and/or	endometrial	biopsy	recommended	with	
persistent	thickened	endometrium	and/or	risk	factors	including	prolonged	amenorrhea,	abnormal	vaginal	bleeding	
or	excess	weight.	However,	routine	ultrasound	screening	of	endometrial	thickness	in	PCOS	is	not	recommended
–
CPP Optimal	prevention	for	endometrial	hyperplasia	and	endometrial	cancer	is	not	known.	A	pragmatic	approach	
could	include	COCP	or	progestin	therapy	in	those	with	cycles	longer	than	90	days
–
2.	Prevalence,	screening,	diagnostic	assessment	and	treatment	in	emotional	wellbeing
Quality	of	life
CCR Health	professionals	and	women	should	be	aware	of	the	adverse	impact	of	PCOS	on	quality	of	life ****
CCR Health	professionals	should	capture	and	consider	perceptions	of	symptoms,	impact	on	quality	of	life	and	
personal	priorities	for	care	to	improve	patient	outcomes
****
CPP The	PCOS	quality	of	life	tool	(PCOSQ),	or	the	modified	PCOSQ,	may	be	useful	clinically	to	highlight	PCOS	features	
causing	greatest	distress,	and	to	evaluate	treatment	outcomes	on	women’s	subjective	PCOS	health	concerns
–
Depressive	and	anxiety	symptoms,	screening	and	treatment
CCR Health	professionals	should	be	aware	that	in	PCOS,	there	is	a	high	prevalence	of	moderate	to	severe	anxiety	
and	depressive	symptoms	in	adults;	and	a	likely	increased	prevalence	in	adolescents
****
CCR Anxiety	and	depressive	symptoms	should	be	routinely	screened	in	all	adolescents	and	women	with	PCOS	at	
diagnosis.	If	the	screen	for	these	symptoms	and/or	other	aspects	of	emotional	wellbeing	is	positive,	further	
assessment	and/or	referral	for	assessment	and	treatment	should	be	completed	by	suitably	qualified	health	
professionals,	informed	by	regional	guidelines
****
CCR If	treatment	is	warranted,	psychological	therapy	and/or	pharmacological	treatment	should	be	offered	in	PCOS,	
informed	by	regional	clinical	practice	guidelines
****
CPP The	optimal	interval	for	anxiety	and	depressive	symptom	screening	is	not	known.	A	pragmatic	approach	could	
include	repeat	screening	using	clinical	judgment,	considering	risk	factors,	comorbidities	and	life	events
–
CPP Assessment	of	anxiety	and	or	depressive	symptoms	involves	assessment	of	risk	factors,	symptoms	and	severity.	
Symptoms	can	be	screened	according	to	regional	guidelines,	or	by	using	simple	stepwise	approaches	(see	full	
guideline	for	details)
–
CPP Where	pharmacological	treatment	for	anxiety	and	depression	is	offered	in	PCOS,	the	following	need	
consideration:	
•	 Caution	is	needed	to	avoid	inappropriate	treatment	with	antidepressants	or	anxiolytics.	Where	mental	health	
disorders	are	clearly	documented	and	persistent,	or	if	suicidal	symptoms	are	present,	treatment	of	depression	
or	anxiety	need	to	be	informed	by	clinical	regional	practice	guidelines.
•	 Use	of	agents	that	exacerbate	PCOS	symptoms,	including	weight	gain,	need	careful	consideration.
–
CPP Factors	including	obesity,	infertility,	and	hirsutism	need	consideration	along	with	use	of	hormonal	medications	
in	PCOS,	as	they	may	independently	exacerbate	depressive	and	anxiety	symptoms	and	other	aspects	of	
emotional	wellbeing
–
Psychosexual	function
CCR All	health	professionals	should	be	aware	of	the	increased	prevalence	of	psychosexual	dysfunction	and	should	
consider	exploring	how	features	of	PCOS,	including	hirsutism	and	body	image,	impact	on	sex	life	and	
relationships	in	PCOS
****
CCR If	psychosexual	dysfunction	is	suspected,	tools	such	as	the	Female	Sexual	Function	Index	can	be	considered ****
Body	image
CCR Health	professionals	and	women	should	be	aware	that	features	of	PCOS	can	impact	on	body	image ***
CPP Negative	body	image,	can	be	screened	according	to	regional	guidelines	or	by	using	a	stepped	approach	(see	full	
guideline	for	details)
–
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Eating	disorders	and	disordered	eating
CCR All	health	professionals	and	women	should	be	aware	of	the	increased	prevalence	of	eating	disorders	and	
disordered	eating	associated	with	PCOS
**
CCR If	eating	disorders	and	disordered	eating	are	suspected,	further	assessment,	referral	and	treatment,	including	
psychological	therapy,	could	be	offered	by	appropriately	trained	health	professionals,	informed	by	regional	
guidelines	or	by	using	a	stepped	approach	(see	full	guideline	for	details)
**
Information	resources,	models	of	care,	cultural	and	linguistic	considerations
CCR Information	and	education	resources	for	women	with	PCOS	should	be	culturally	appropriate,	tailored	and	
high-	quality,	should	use	a	respectful	and	empathetic	approach,	and	promote	self-	care	and	highlight	peer	
support	groups
****
CCR Information	and	education	resources	for	healthcare	professionals	should	promote	the	recommended	diagnostic	
criteria,	appropriate	screening	for	comorbidities,	and	effective	lifestyle	and	pharmacological	management
****
CCR PCOS	information	should	be	comprehensive,	evidence-	based,	and	inclusive	of	the	biopsychosocial	dimensions	
of	PCOS	across	the	life-	span
****
CCR Women’s	needs,	communication	preferences,	beliefs,	and	culture	should	be	considered	and	addressed	through	
provision	of	culturally	and	linguistically	appropriate	co-	designed	resources	and	care
****
CPP Interdisciplinary	care	needs	to	be	considered	for	those	with	PCOS	where	appropriate	and	available.	Primary	
care	is	generally	well	placed	to	diagnose,	screen	and	coordinate	interdisciplinary	care
–
CPP Care	needs	to	be	person	centered,	address	women’s	priorities	and	be	provided	in	partnership	with	those	with	
PCOS	and	where	appropriate,	their	families
–
CPP Guideline	dissemination	and	translation	including	multimodal	education	tools	and	resources	is	important,	with	
consultation	and	engagement	with	stakeholders	internationally
–
3.	Lifestyle
Effectiveness	of	lifestyle	interventions
CCR Healthy	lifestyle	behaviors	encompassing	healthy	eating	and	regular	physical	activity	should	be	recommended	
in	all	those	with	PCOS	to	achieve	and/or	maintain	healthy	weight	and	to	optimize	hormonal	outcomes,	general	
health,	and	quality	of	life	across	the	life	course
****
EBR Lifestyle	intervention	(preferably	multicomponent	including	diet,	exercise	and	behavioral	strategies)	should	be	
recommended	in	all	those	with	PCOS	and	excess	weight,	for	reductions	in	weight,	central	obesity	and	insulin	
resistance
*** 
⊕⊕○○
CPP Achievable	goals	such	as	5%	to	10%	weight	loss	in	those	with	excess	weight	yields	significant	clinical	 
improvements	and	is	considered	successful	weight	reduction	within	six	months.	Ongoing	assessment	and	
monitoring	is	important	during	weight	loss	and	maintenance	in	all	women	with	PCOS
–
CPP SMART	(Specific	Measurable,	Achievable,	Realistic	and	Timely)	goal	setting	and	self-	monitoring	can	enable	
achievement	of	realistic	lifestyle	goals
–
CPP Psychological	factors	such	as	anxiety	and	depressive	symptoms,	body	image	concerns	and	disordered	eating,	need	
consideration	and	management	to	optimize	engagement	and	adherence	to	lifestyle	interventions
–
CPP Health	professional	interactions	around	healthy	lifestyle,	including	diet	and	exercise,	need	to	be	respectful,	
patient-	centred	and	to	value	women’s	individualised	healthy	lifestyle	preferences	and	cultural,	socioeconomic	
and	ethnic	differences.	Health	professionals	need	to	also	consider	personal	sensitivities,	marginalisation	and	
potential	weight-	related	stigma
–
CPP Adolescent	and	ethnic-	specific	BMI	and	waist	circumference	categories	need	to	be	considered	when	optimising	
lifestyle	and	weight
–
CPP Healthy	lifestyle	may	contribute	to	health	and	quality	of	life	benefits	in	the	absence	of	weight	loss –
CPP Healthy	lifestyle	and	optimal	weight	management	appears	equally	effective	in	PCOS	as	in	the	general	popula-
tion	and	is	the	joint	responsibility	of	all	health	professionals,	partnering	with	women	with	PCOS.	Where	
complex	issues	arise,	referral	to	suitably	trained	allied	health	professionals	needs	to	be	considered
–
CPP Ethnic	groups	with	PCOS	who	are	at	high	cardiometabolic	risk	require	greater	consideration	in	terms	of	healthy	
lifestyle	and	lifestyle	intervention	(see	Ethnic	Variation)
–
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Behavioral	strategies
CCR Lifestyle	interventions	could	include	behavioral	strategies	such	as	goal-	setting,	self-	monitoring,	stimulus	control,	
problem	solving,	assertiveness	training,	slower	eating,	reinforcing	changes	and	relapse	prevention,	to	optimize	
weight	management,	healthy	lifestyle	and	emotional	wellbeing	in	women	with	PCOS
****
CPP Comprehensive	health	behavioral	or	cognitive	behavioral	interventions	could	be	considered	to	increase	support,	
engagement,	retention,	adherence	and	maintenance	of	healthy	lifestyle	and	improve	health	outcomes	in	
women	with	PCOS
–
Dietary	intervention
CCR A	variety	of	balanced	dietary	approaches	could	be	recommended	to	reduce	dietary	energy	intake	and	induce	
weight	loss	in	women	with	PCOS	and	overweight	and	obesity,	as	per	general	population	recommendations
****
CCR General	healthy	eating	principles	should	be	followed	for	all	women	with	PCOS	across	the	life	course,	as	per	
general	population	recommendations
****
CPP To	achieve	weight	loss	in	those	with	excess	weight,	an	energy	deficit	of	30%	or	500-	750	kcal/day	 
(1200-	1500	kcal/day)	could	be	prescribed	for	women,	also	considering	individual	energy	requirements,	 
body	weight	and	physical	activity	levels
–
CPP In	women	with	PCOS,	there	is	no	or	limited	evidence	that	any	specific	energy	equivalent	diet	type	 
is	better	than	another,	or	that	there	is	any	differential	response	to	weight	management	intervention,	compared	
to	women	without	PCOS
–
CPP Tailoring	of	dietary	changes	to	food	preferences,	allowing	for	a	flexible	and	individual	approach	to	reducing	
energy	intake	and	avoiding	unduly	restrictive	and	nutritionally	unbalanced	diets,	are	important,	as	per	general	
population	recommendations
–
Exercise	intervention
CCR Health	professionals	should	encourage	and	advise	the	following	for	prevention	of	weight	gain	and	maintenance	
of	health:	
•	 In	adults	from	18	to	64	years,	a	minimum	of	150	min/wk	of	moderate	intensity	physical	activity	or	 
75	min/week	of	vigorous	intensities	or	an	equivalent	combination	of	both,	including	muscle	strengthening	
activities	on	2	non-consecutive	days/week.
•	 In	adolescents,	at	least	60	minutes	of	moderate	to	vigorous	intensity	physical	activity/day,	including	those	
that	strengthen	muscle	and	bone	at	least	3	times	weekly.
•	 Activity	be	performed	in	at	least	10-minute	bouts	or	around	1000	steps,	aiming	to	achieve	at	least	
30	minutes	daily	on	most	days.
***
CCR Health	professionals	should	encourage	and	advise	the	following	for	modest	weight-	loss,	prevention	of	
weight-	regain	and	greater	health	benefits:	
•	 A	minimum	of	250	min/week	of	moderate	intensity	activities	or	150	min/week	of	vigorous	intensity	or	an	
equivalent	combination	of	both,	and	muscle	strengthening	activities	involving	major	muscle	groups	on	two	
non-consecutive	days/week.
•	 Minimized	sedentary,	screen,	or	sitting	time.
***
CPP Physical	activity	includes	leisure	time	physical	activity,	transportation	such	as	walking	or	cycling,	occupational	
work,	household	chores,	games,	sports	or	planned	exercise,	in	the	context	of	daily,	family	and	community	
activities.	Daily,	10000	steps	is	ideal,	including	activities	of	daily	living	and	30	min	of	structured	physical	
activity	or	around	3000	steps.	Structuring	of	recommended	activities	need	to	consider	women’s	and	family	
routines	as	well	as	cultural	preferences
–
CPP Realistic	physical	activity	SMART	(Specific,	Measureable,	Achievable,	Relevant,	Time	limited)	goals	could	include	
10	min	bouts,	progressively	increasing	physical	activity	5%	weekly,	up	to	and	above	recommendations
–
CPP Self-	monitoring	including	with	fitness	tracking	devices	and	technologies	for	step	count	and	exercise	intensity,	
could	be	used	as	an	adjunct	to	support	and	promote	active	lifestyles	and	minimize	sedentary	behaviors
–
Obesity	and	weight	assessment
CCR Health	professionals	and	women	should	be	aware	that	women	with	PCOS	have	a	higher	prevalence	of	weight	
gain	and	obesity,	presenting	significant	concerns	for	women,	impacting	on	health	and	emotional	wellbeing,	
with	a	clear	need	for	prevention
***
CCR All	those	with	PCOS	should	be	offered	regular	monitoring	for	weight	changes	and	excess	weight	(see	
Cardiovascular	Disease	Risk)
****
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CPP When	assessing	weight,	related	stigma,	negative	body	image	and/or	low	self-	esteem	need	to	be	considered	and	
assessment	needs	to	be	respectful	and	considerate.	Beforehand,	explanations	on	the	purpose	and	how	the	
information	will	be	used	and	the	opportunity	for	questions	and	preferences	needs	to	be	provided,	permission	
sought	and	scales	and	tape	measures	adequate.	Implications	of	results	need	to	be	explained	and	where	this	
impacts	on	emotional	wellbeing,	support	provided
–
CPP Prevention	of	weight	gain,	monitoring	of	weight	and	encouraging	evidence-	based	and	socio-	culturally	appropri-
ate	healthy	lifestyle	is	important	in	PCOS,	particularly	from	adolescence
–
4.	Pharmacological	treatment	for	non-	fertility	indications
Pharmacological	treatment	principles	in	PCOS
CPP Consideration	of	the	individual’s	personal	characteristics,	preferences	and	values	is	important	in	recommending	
pharmacological	treatment
–
CPP When	prescribing	pharmacological	therapy	in	PCOS,	benefits,	adverse	effects	and	contraindications	in	PCOS	
and	general	populations	need	to	be	considered	and	discussed	before	commencement
–
CPP COCPs,	metformin	and	other	pharmacological	treatments	are	generally	off	label#	in	PCOS.	However	off	label	
use	is	predominantly	evidence-	based	and	is	allowed	in	many	countries.	Where	is	it	allowed,	health	profession-
als	need	to	inform	women	and	discuss	the	evidence,	possible	concerns	and	side	effects	of	treatment
–
CPP Holistic	approaches	are	required	and	pharmacological	therapy	in	PCOS	needs	to	be	considered	alongside	
education,	lifestyle	and	other	options	including	cosmetic	therapy	and	counselling
–
Combined	oral	contraceptive	pills	(COCPs)
EBR The	COCP	alone	should	be	recommended	in	adult	women	with	PCOS	for	management	of	hyperandrogenism	
and/or	irregular	menstrual	cycles
****⊕⊕○○
EBR The	COCP	alone	should	be	considered	in	adolescents	with	a	clear	diagnosis	of	PCOS	for	management	of	clinical	
hyperandrogenism	and/or	irregular	menstrual	cycles
***⊕⊕○○
EBR The	COCP	could	be	considered	in	adolescents	who	are	deemed	“at	risk”	but	not	yet	diagnosed	with	PCOS,	for	
management	of	clinical	hyperandrogenism	and	irregular	menstrual	cycles
****⊕⊕○○
EBR Specific	types	or	dose	of	progestins,	estrogens	or	combinations	of	COCP	cannot	currently	be	recommended	in	
adults	and	adolescents	with	PCOS	and	practice	should	be	informed	by	general	population	guidelines
****⊕⊕○○
CCR The	35	microgram	ethinyloestradiol	plus	cyproterone	acetate	preparations	should	not	be	considered	first	line	in	
PCOS	as	per	general	population	guidelines,	due	to	adverse	effects	including	venous	thromboembolic	risks
*
CPP When	prescribing	COCPs	in	adults	and	adolescents	with	PCOS:	
•	 Various	COCP	preparations	have	similar	efficacy	in	treating	hirsutism.
•	 The	lowest	effective	estrogen	doses	(such	as	20-30	micrograms	of	ethinyloestradiol	or	equivalent),	and	
natural	estrogen	preparations	are	preferred,	balancing	efficacy,	metabolic	risk	profile,	side	effects,	cost	
and	availability.
•	 The	generally	limited	evidence	on	effects	of	COCPs	in	PCOS	needs	to	be	appreciated	with	practice	
informed	by	general	population	guidelines	(WHO	Guidelines).
•	 The	relative	and	absolute	contraindications	and	side	effects	of	COCPs	need	to	be	considered	and	be	the	
subject	of	individualized	discussion.
•	 PCOS	specific	risk	factors	such	as	high	BMI,	hyperlipidemia	and	hypertension	need	to	be	considered.
–
Combined	oral	contraceptive	pills	in	combination	with	metformin	and/or	anti-	androgen	pharmacological	agents
EBR In	combination	with	the	COCP,	metformin	should	be	considered	in	women	with	PCOS	for	management	of	
metabolic	features	where	COCP	and	lifestyle	changes	do	not	achieve	desired	goals
****
⊕⊕○○
EBR In	combination	with	the	COCP,	metformin	could	be	considered	in	adolescents	with	PCOS	and	BMI	≥25	kg/m2 
where	COCP	and	lifestyle	changes	do	not	achieve	desired	goals
****
⊕⊕○○
CPP In	combination	with	the	COCP,	metformin	may	be	most	beneficial	in	high	metabolic	risk	groups	including	those	
with	diabetes	risk	factors,	impaired	glucose	tolerance,	or	high-	risk	ethnic	groups
–
EBR In	combination	with	the	COCP,	antiandrogens	should	only	be	considered	in	PCOS	to	treat	hirsutism,	after	six	
months	or	more	of	COCP	and	cosmetic	therapy	have	failed	to	adequately	improve	symptoms
**
⊕⊕○○
CCR In	combination	with	the	COCP,	antiandrogens	could	be	considered	for	the	treatment	of	androgen-	related	
alopecia	in	PCOS
**
CPP In	PCOS,	antiandrogens	must	be	used	with	effective	contraception,	to	avoid	male	foetal	undervirilisation.	
Variable	availability	and	regulatory	status	of	these	agents	is	notable	and	for	some	agents,	potential	liver	
toxicity	requires	caution
–
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Metformin
EBR Metformin	in	addition	to	lifestyle,	could	be	recommended	in	adult	women	with	PCOS,	for	the	treatment	of	
weight,	hormonal,	and	metabolic	outcomes
***
⊕⊕○○
EBR Metformin	in	addition	to	lifestyle,	should	be	considered	in	adult	women	with	PCOS	with	BMI	≥25	kg/m2	for	
management	of	weight	and	metabolic	outcomes
***
⊕⊕○○
EBR Metformin	in	additional	to	lifestyle,	could	be	considered	in	adolescents	with	a	clear	diagnosis	of	PCOS	or	with	
symptoms	of	PCOS	before	the	diagnosis	is	made
***
⊕⊕○○
CPP Metformin	may	offer	greater	benefit	in	high	metabolic	risk	groups	including	those	with	diabetes	risk	factors,	
impaired	glucose	tolerance	or	high-	risk	ethnic	groups	(see	Ethnic	variation)
–
CPP Where	metformin	is	prescribed	the	following	need	to	be	considered:	
•	 Adverse	effects,	including	gastrointestinal	side-effects	that	are	generally	dose	dependent	and	 
self-limiting,	need	to	be	the	subject	of	individualized	discussion.
•	 Starting	at	a	low	dose,	with	500	mg	increments	1-2	weekly	and	extended	release	preparations	may	
minimize	side	effects.
•	 Metformin	use	appears	safe	long-term,	based	on	use	in	other	populations,	however	ongoing	requirement	
needs	to	be	considered	and	use	may	be	associated	with	low	vitamin	B12	levels
•	 Use	is	generally	off	label	and	health	professionals	need	to	inform	women	and	discuss	the	evidence,	
possible	concerns	and	side	effects.
–
Anti-	obesity	pharmacological	agents
CCR Anti-	obesity	medications	in	addition	to	lifestyle,	could	be	considered	for	the	management	of	obesity	in	adults	
with	PCOS	after	lifestyle	intervention,	as	per	general	population	recommendations
–
CPP For	anti-	obesity	medications,	cost,	contraindications,	side	effects,	variable	availability	and	regulatory	status	
need	to	be	considered	and	pregnancy	needs	to	be	avoided	whilst	taking	these	medications
–
Anti-	androgen	pharmacological	agents
EBR Where	COCPs	are	contraindicated	or	poorly	tolerated,	in	the	presence	of	other	effective	forms	of	 
contraception,	anti-	androgens	could	be	considered	to	treat	hirsutism	and	androgen-	related	alopecia
***⊕○○○
CPP Specific	types	or	doses	of	anti-	androgens	cannot	currently	be	recommended	with	inadequate	evidence	in	PCOS –
Inositol
EBR Inositol	(in	any	form)	should	currently	be	considered	an	experimental	therapy	in	PCOS,	with	emerging	evidence	
on	efficacy	highlighting	the	need	for	further	research
*⊕○○○
CPP Women	taking	inositol	and	other	complementary	therapies	are	encouraged	to	advise	their	health	professional –
5.	Assessment	and	treatment	of	infertility
Assessment	of	factors	that	may	affect	fertility,	treatment	response,	or	pregnancy	outcomes
CPP Factors	such	as	blood	glucose,	weight,	blood	pressure,	smoking,	alcohol,	diet,	exercise,	sleep	and	mental,	
emotional	and	sexual	health	need	to	be	optimized	in	women	with	PCOS,	to	improve	reproductive	and	obstetric	
outcomes,	aligned	with	recommendations	in	the	general	population.	Refer	to	Lifestyle,	Emotional	Wellbeing	
and	Diabetes	risk	sections
–
CPP Monitoring	during	pregnancy	is	important	in	women	with	PCOS,	given	increased	risk	of	adverse	maternal	and	
offspring	outcomes
–
CCR In	women	with	PCOS	and	infertility	due	to	anovulation	alone	with	normal	semen	analysis,	the	risks,	benefits,	
costs	and	timing	of	tubal	patency	testing	should	be	discussed	on	an	individual	basis
***
CCR Tubal	patency	testing	should	be	considered	prior	to	ovulation	induction	in	women	with	PCOS	where	there	is	
suspected	tubal	infertility
***
Ovulation	induction	principles
CPP The	use	of	ovulation	induction	agents,	including	letrozole,	metformin	and	clomiphene	citrate	is	off	label	in	many	
countries.	Where	off	label	use	of	ovulation	induction	agents	is	allowed,	health	professionals	need	to	inform	
women	and	discuss	the	evidence,	possible	concerns	and	side	effects
–
CPP Pregnancy	needs	to	be	excluded	prior	to	ovulation	induction –
CPP Unsuccessful,	prolonged	use	of	ovulation	induction	agents	need	to	be	avoided,	due	to	poor	success	rates –
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Letrozole
EBR Letrozole	should	be	considered	first	line	pharmacological	treatment	for	ovulation	induction	in	women	with	
PCOS	with	anovulatory	infertility	and	no	other	infertility	factors	to	improve	ovulation,	pregnancy	and	live	 
birth	rates
****
⊕⊕○○
CPP Where	letrozole	is	not	available	or	use	is	not	permitted	or	cost	is	prohibitive,	health	professionals	can	use	other	
ovulation	induction	agents
–
CPP Health	professionals	and	women	need	to	be	aware	that	the	risk	of	multiple	pregnancy	appears	to	be	less	with	
letrozole,	compared	to	clomiphene	citrate
–
Clomiphene	citrate	and	metformin
EBR Clomiphene	citrate	could	be	used	alone	in	women	with	PCOS	with	anovulatory	infertility	and	no	other	infertility	
factors	to	improve	ovulation	and	pregnancy	rates
***⊕○○○
EBR Metformin	could	be	used	alone	in	women	with	PCOS,	with	anovulatory	infertility	and	no	other	infertility	
factors,	to	improve	ovulation,	pregnancy	and	live	birth	rates,	although	women	should	be	informed	that	there	
are	more	effective	ovulation	induction	agents
***⊕⊕⊕○
EBR Clomiphene	citrate	could	be	used	in	preference,	when	considering	clomiphene	citrate	or	metformin	for	
ovulation	induction	in	women	with	PCOS	who	are	obese	(BMI	is	≥30	kg/m2)	with	anovulatory	infertility	and	no	
other	infertility	factors
***⊕⊕○○
EBR If	metformin	is	being	used	for	ovulation	induction	in	women	with	PCOS	who	are	obese	(BMI	≥30	kg/m2)	with	
anovulatory	infertility	and	no	other	infertility	factors,	clomiphene	citrate	could	be	added	to	improve	ovulation,	
pregnancy	and	live	birth	rates
***⊕⊕○○
EBR Clomiphene	citrate	could	be	combined	with	metformin,	rather	than	persisting	with	clomiphene	citrate	alone,	in	
women	with	PCOS	who	are	clomiphene	citrate-	resistant,	with	anovulatory	infertility	and	no	other	infertility	
factors,	to	improve	ovulation	and	pregnancy	rates
***⊕⊕○○
CPP The	risk	of	multiple	pregnancies	is	increased	with	clomiphene	citrate	use	and	therefore	monitoring	needs	to	be	
considered
–
Gonadotrophins
EBR Gonadotrophins	could	be	used	as	second	line	pharmacological	agents	in	women	with	PCOS	who	have	failed	first	
line	oral	ovulation	induction	therapy	and	are	anovulatory	and	infertile,	with	no	other	infertility	factors
***⊕⊕○○
EBR Gonadotrophins	could	be	considered	as	first	line	treatment,	in	the	presence	of	ultrasound	monitoring,	following	
counselling	on	cost	and	potential	risk	of	multiple	pregnancy,	in	women	with	PCOS	with	anovulatory	infertility	
and	no	other	infertility	factors
***⊕⊕○○
EBR Gonadotrophins,	where	available	and	affordable,	should	be	used	in	preference	to	clomiphene	citrate	combined	
with	metformin	therapy	for	ovulation	induction,	in	women	with	PCOS	with	anovulatory	infertility,	clomiphene	
citrate-	resistance	and	no	other	infertility	factors,	to	improve	ovulation,	pregnancy	and	live	birth	rates
****⊕⊕⊕○
EBR Gonadotrophins	with	the	addition	of	metformin	could	be	used	rather	than	gonadotrophin	alone,	in	women	with	
PCOS	with	anovulatory	infertility,	clomiphene	citrate-	resistance	and	no	other	infertility	factors,	to	improve	
ovulation,	pregnancy	and	live	birth	rates
***⊕⊕⊕○
EBR Either	gonadotrophins	or	laparoscopic	ovarian	surgery	could	be	used	in	women	with	PCOS	with	anovulatory	
infertility,	clomiphene	citrate-	resistance	and	no	other	infertility	factors,	following	counselling	on	benefits	and	
risks	of	each	therapy
****⊕⊕⊕○
CPP Where	gonadotrophins	are	prescribed,	considerations	include:	
•	 Cost	and	availability.
•	 Expertise	required	for	use	in	ovulation	induction.
•	 Degree	of	intensive	ultrasound	monitoring	required.
•	 Lack	of	difference	in	clinical	efficacy	of	available	gonadotrophin	preparations.
•	 Low	dose	gonadotrophin	protocols	optimize	monofollicular	development.
•	 Risk	and	implications	of	potential	multiple	pregnancy.
–
CPP Gonadotrophin	induced	ovulation	is	only	triggered	when	there	are	fewer	than	three	mature	follicles	and	needs	
to	be	cancelled	if	there	are	more	than	two	mature	follicles	with	the	patient	advised	to	avoid	unprotected	
intercourse
–
Anti-	obesity	pharmacological	agents
CCR Pharmacological	anti-	obesity	agents	should	be	considered	an	experimental	therapy	in	women	with	PCOS	for	the	
purpose	of	improving	fertility,	with	risk	to	benefit	ratios	currently	too	uncertain	to	advocate	this	as	fertility	
therapy
*
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Laparoscopic	surgery
EBR Laparoscopic	ovarian	surgery	could	be	second	line	therapy	for	women	with	PCOS,	who	are	clomiphene	citrate	
resistant,	with	anovulatory	infertility	and	no	other	infertility	factors
***⊕⊕○○
CCR Laparoscopic	ovarian	surgery	could	potentially	be	offered	as	first	line	treatment	if	laparoscopy	is	indicated	for	
another	reason	in	women	with	PCOS	with	anovulatory	infertility	and	no	other	infertility	factors
***
CPP Risks	need	to	be	explained	to	all	women	with	PCOS	considering	laparoscopic	ovarian	surgery –
CPP Where	laparoscopic	ovarian	surgery	is	to	be	recommended,	the	following	need	to	be	considered:
•	 Comparative	cost.
•	 Expertise	required	for	use	in	ovulation	induction.
•	 Intra-operative	and	post-operative	risks	are	higher	in	women	who	are	overweight	and	obese.
•	 There	may	be	a	small	associated	risk	of	lower	ovarian	reserve	or	loss	of	ovarian	function.
•	 Periadnexal	adhesion	formation	may	be	an	associated	risk.
–
Bariatric	surgery
CCR Bariatric	surgery	should	be	considered	an	experimental	therapy	in	women	with	PCOS,	for	the	purpose	of	having	
a	healthy	baby,	with	risk	to	benefit	ratios	currently	too	uncertain	to	advocate	this	as	fertility	therapy
*
CPP If	bariatric	surgery	is	to	be	prescribed,	the	following	need	to	be	considered:	
•	 Comparative	cost.
•	 The	need	for	a	structured	weight	management	program	involving	diet,	physical	activity	and	interventions	
to	improve	psychological,	musculoskeletal	and	cardiovascular	health	to	continue	post-operatively.
•	 Perinatal	risks	such	as	small	for	gestational	age,	premature	delivery,	possibly	increased	infant	mortality.
•	 Potential	benefits	such	as	reduced	incidence	of	large	for	gestational	age	fetus	and	gestational	diabetes.
•	 Recommendations	for	pregnancy	avoidance	during	periods	of	rapid	weight	loss	and	for	at	least	12	months	
after	bariatric	surgery	with	appropriate	contraception.
 
If	pregnancy	occurs,	the	following	need	to	be	considered:	
•	 Awareness	and	preventative	management	of	pre-and	post-operative	nutritional	deficiencies	is	important,	
ideally	in	a	specialist	interdisciplinary	care	setting.
•	 Monitoring	of	fetal	growth	during	pregnancy.
–
In	vitro	fertilization	(IVF)
CCR In	the	absence	of	an	absolute	indication	for	IVF	±	intracytoplasmic	sperm	injection	(ICSI),	women	with	PCOS	
and	anovulatory	infertility	could	be	offered	IVF	as	third	line	therapy	where	first	or	second	line	ovulation	
induction	therapies	have	failed
***
CPP In	women	with	anovulatory	PCOS,	the	use	of	IVF	is	effective	and	when	elective	single	embryo	transfer	is	used,	
multiple	pregnancies	can	be	minimized
–
CPP Women	with	PCOS	undergoing	IVF	±	ICSI	therapy	need	to	be	counselled	prior	to	starting	treatment	including	
on: 
•	 Availability,	cost	and	convenience.
•	 Increased	risk	of	ovarian	hyperstimulation	syndrome.
•	 Options	to	reduce	the	risk	of	ovarian	hyperstimulation.
–
CCR Urinary	or	recombinant	follicle	stimulation	hormone	can	be	used	in	women	with	PCOS	undergoing	controlled	
ovarian	hyperstimulation	for	IVF	±	ICSI,	with	insufficient	evidence	to	recommend	specific	follicle	stimulating	
hormone	(FSH)	preparations
–
CCR Exogenous	recombinant	luteinizing	hormone	treatment	should	not	be	routinely	used	in	combination	with	follicle	
stimulating	hormone	therapy	in	women	with	PCOS	undergoing	controlled	ovarian	hyperstimulation	for	
IVF	±	ICSI
–
EBR A	gonadotrophin	releasing	hormone	antagonist	protocol	is	preferred	in	women	with	PCOS	undergoing	an	
IVF	±	ICSI	cycle,	over	a	gonadotrophin	releasing	hormone	agonist	long	protocol,	to	reduce	the	duration	of	
stimulation,	total	gonadotrophin	dose	and	incidence	of	ovarian	hyperstimulation	syndrome	(OHSS)
***⊕⊕○○
CPP Human	chorionic	gonadotrophins	is	best	used	at	the	lowest	doses	to	trigger	final	oocyte	maturation	in	women	
with	PCOS	undergoing	an	IVF	±	ICSI	cycle	to	reduce	the	incidence	of	OHSS
–
CPP Triggering	final	oocyte	maturation	with	a	gonadotropin-	releasing	hormone	(GnRH)	agonist	and	freezing	all	
suitable	embryos	could	be	considered	in	women	with	PCOS	having	an	IVF/ICSI	cycle	with	a	GnRH	antagonist	
protocol	and	at	an	increased	risk	of	developing	OHSS	or	where	fresh	embryo	transfer	is	not	planned
–
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multidisciplinary	clinical	expertise,	consumer	preferences	and	struc-
tured	 review	by	 the	 five	GDGs.	Detailed	methods	 for	 stakeholder	
engagement	 and	 guideline	 development	 can	 be	 found	 at	 https://
www.monash.edu/medicine/sphpm/mchri/pcos.	The	guideline	pro-
vides	 166	 recommendations:	 EBR	=	31,	 CCR	=	59,	 and	 CPP	=	76.	
Overall	evidence	is	low	to	moderate	quality,	requiring	significant	re-
search	expansion	in	this	neglected,	yet	common	condition.
We	endorse	 the	Rotterdam	PCOS	Diagnostic	Criteria	 in	adults	
(two	of	oligo-	or	anovulation,	clinical	and/or	biochemical	hyperan-
drogenism,	or	polycystic	ovaries	on	ultrasound),	 after	exclusion	of	
related	disorders.	Where	both	oligo-	or	anovulation	and	hyperandro-
genism	are	present,	ultrasound	is	not	necessary	for	diagnosis.	In	ado-
lescents,	both	oligo-	anovulation	and	hyperandrogenism	are	required,	
with	ultrasound	not	recommended	for	diagnosis.	Ultrasound	criteri-
ons	are	refined	with	advancing	technology.	Antimüllerian	hormone	
levels	are	not	yet	adequate	for	diagnosis	of	PCOS.	Insulin	resistance	
is	recognized	as	a	key	feature	of	PCOS,	yet	clinical	measurement	is	
not	recommended	at	the	current	time.	Once	diagnosed,	assessment	
and	management	includes	reproductive,	metabolic,	and	psycholog-
ical	 features.	Education,	 self-	empowerment,	multidisciplinary	care,	
and	 lifestyle	 intervention	for	prevention	or	management	of	excess	
weight	are	prioritized.	Depressive	and	anxiety	symptoms	should	be	
screened,	 assessed	 and	managed	 and	 health	 professionals	 should	
be	 aware	 of	 other	 impacts	 on	 emotional	wellbeing	 and	 quality	 of	
life.	Combined	oral	contraceptive	pills	are	first-	line	pharmacological	
management	for	menstrual	irregularity	and	hyperandrogenism,	with	
no	specific	 formulation	recommended	and	with	 low	dose	prepara-
tions	preferred.	Metformin	is	recommended	in	addition	or	alone,	pri-
marily	for	management	of	metabolic	features.	Letrozole	is	first-	line	
pharmacological	infertility	therapy;	with	clomiphene	and	metformin	
both	having	a	role	alone	and	in	combination.	In	women	with	PCOS	
and	 anovulatory	 infertility,	 gonadotrophins	 are	 second	 line.	 In	 the	
absence	of	 an	absolute	 indication	 for	 IVF,	women	with	PCOS	and	
anovulatory	 infertility,	could	be	offered	 IVF	third	 line	where	other	
ovulation	induction	therapies	have	failed.
The	 combined	 effects	 of	 the	 provision	 of	 a	 single	 source	 of	
evidence-	based	 recommendations	 and	 comprehensive	 international	
translation	and	dissemination	program	will	amplify	impact	of	the	guide-
line	 and	 recommendations	 globally.	 It	will	 support	 and	build	 the	 ca-
pability	of	health	professionals	to	deliver	high-	quality,	evidence-	based	
Category Recommendation
GRADE and 
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CPP In	IVF	±	ICSI	cycles	in	women	with	PCOS,	consideration	needs	to	be	given	to	an	elective	freeze	of	all	embryos –
EBR Adjunct	metformin	therapy	could	be	used	before	and/or	during	follicle	stimulating	hormone	ovarian	stimulation	
in	women	with	PCOS	undergoing	a	IVF	±	ICSI	therapy	with	a	GnRH	agonist	protocol,	to	improve	the	clinical	
pregnancy	rate	and	reduce	the	risk	of	OHSS
***⊕⊕○○
CCR In	a	GnRH	agonist	protocol	with	adjunct	metformin	therapy,	in	women	with	PCOS	undergoing	IVF	±	ICSI	
treatment,	the	following	could	be	considered:	
•	 Metformin	commencement	at	the	start	of	GnRH	agonist	treatment.
•	 Metformin	use	at	a	dose	of	between	1000	to	2550	mg	daily.
•	 Metformin	cessation	at	the	time	of	the	pregnancy	test	or	menses	(unless	the	metformin	therapy	is	
otherwise	indicated).
•	 Metformin	side-effects	(see	metformin	section	in	this	table)
–
CPP In	IVF	±	ICSI	cycles,	women	with	PCOS	could	be	counselled	on	potential	benefits	of	adjunct	metformin	in	a	
GnRH	antagonist	protocol	to	reduce	risk	of	ovarian	hyperstimulation	syndrome	(see	above	for	metformin	
therapy	considerations).
–
CPP The	term	in	vitro	maturation	(IVM)	treatment	cycle	is	applied	to	“the	maturation	in	vitro	of	immature	cumulus	
oocyte	complexes	collected	from	antral	follicles”	(encompassing	both	stimulated	and	unstimulated	cycles,	but	
without	the	use	of	a	human	gonadotrophin	trigger)
–
CCR In	units	with	sufficient	expertise,	IVM	could	be	offered	to	achieve	pregnancy	and	livebirth	rates	approaching	
those	of	standard	IVF	±	ICSI	treatment	without	the	risk	of	OHSS	for	women	with	PCOS,	where	an	embryo	is	
generated,	then	vitrified	and	thawed	and	transferred	in	a	subsequent	cycle
**
EBR,	Evidence	based	recommendation;	CCR,	Clinical	consensus	recommendation;	CPP,	Clinical	Practice	Point.	Evidence	quality:	⊕⊕⊕⊕	=	high	quality,	
⊕⊕⊕○	=	moderate	quality,	⊕⊕○○	=	low	quality	and	⊕○○○	=	very	low	quality	evidence.	****	Strong	recommendation	for	the	option,	***Conditional	
recommendation	for	the	option;	**Conditional	recommendation	for	either	the	option	or	the	comparison;	*Conditional	recommendation	against	the	
option.		Note:	Off-label	prescribing	occurs	when	a	drug	is	prescribed	for	an	indication,	a	route	of	administration,	or	a	patient	group	that	is	not	included	
in	the	approved	product	information	document	for	that	drug	by	the	regulatory	body.	Prescribing	off-label	is	often	unavoidable	and	common,	and	does	
not	mean	that	the	regulatory	body	has	rejected	the	indication,	but	more	commonly	there	has	not	been	a	submission	to	request	evaluation	of	the	indi-
cation	 or	 that	 patient	 group	 for	 any	 given	 drug.	GRADE	working	 group.	Grading	 of	 Recommendations	Assessment,	Development	 and	Evaluation	
(GRADE)	guidelines.
#	Off-	label	prescribing	occurs	when	a	drug	is	prescribed	for	an	indication,	a	route	of	administration,	or	a	patient	group	that	is	not	included	in	the	ap-
proved	product	information	document	for	that	drug	by	the	regulatory	body.	Prescribing	off-	label	is	often	unavoidable	and	common	and	does	not	mean	
that	the	regulatory	body	has	rejected	the	indication,	more	commonly	there	has	not	been	a	submission	to	request	evaluation	of	the	indication	or	that	
patient	group	for	any	given	drug.
TABLE  3  (Continued)
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assessment	 and	management	 of	 PCOS	 and	will	 augment	 the	 health	
literacy	and	self-	management	of	PCOS	health	consumers.	The	guide-
line	 recommendations	 are	 protected	 under	 copyright,	 however	 the	
process	for	adaption	of	guideline	recommendations	to	regional	context	
is	available	at	https://www.monash.edu/medicine/sphpm/mchri/pcos.	
The	guideline	and	translation	program	will	contribute	to	early	diagno-
sis	and	 improved	health	outcomes	and	promote	best-	practice	PCOS	
models	of	care.	The	translation	program	will	be	inclusive	of	a	range	of	
outputs	such	as;	the	first	evidence-	based	PCOS	APP	(AskPCOS),	a	rig-
orously	developed	question	prompt	list	to	optimize	health	professional	
engagement,	 health	 literacy	 enhancing	 tools,	 comprehensive	 PCOS	
related	 health	 information;	 internationally	 accessible	 health	 profes-
sional	accredited	courses,	webinars	with	 international	expert	panels,	
and	e-	health	information	resources	available	at	https://www.monash.
edu/medicine/sphpm/mchri/pcos.	Most	importantly,	the	guideline	and	
translation	of	the	guideline	is	expected	to	improve	patient	experiences	
through	 the	 provision	 of	 timely	 and	 accurate	 diagnosis,	 accessible	
evidence-	based	 information	 and	 improved	multi-	disciplined	 support.	
Ultimately,	this	initiative	may	serve	as	an	exemplar	for	international	col-
laborative	engagement	and	healthcare	impact.	Key	elements	included	
extensive	 collaboration,	 broad	 stakeholder	 representation	 including	
consumer	 partnership,	 distributive	 leadership,	 adequate	 funding,	 ro-
bust	project	management	and	governance,	adherence	to	best	practice	
and	integrated	comprehensive	translation	and	evaluation.
ACKNOWLEDG EMENTS
We	gratefully	acknowledge	the	contribution	of	our	funding,	partner,	
engaged,	and	collaborating	organizations:	
1. The	 Australian	 National	 Health	 and	 Medical	 Research	 Council	
(NHMRC)	 through	 the	 funded	 Centre	 for	 Research	 Excellence	 in	
Polycystic	 Ovary	 Syndrome	 (APP1078444)	 and	 the	 members	 of	
this	 Centre	 who	 coordinated	 this	 international	 guideline	 effort.
2. Our	partner	organizations	which	co-funded	the	guideline:	
•	 American	Society	for	Reproductive	Medicine	(ASRM)
•	 European	 Society	 of	 Human	 Reproduction	 and	 Embryology	
(ESHRE)
3. Our	collaborating	and	engaged	societies	and	consumer	groups:	
•	 Androgen	 Excess	 and	 Polycystic	 Ovary	 Syndrome	 Society	
(AEPCOS)
•	 American	Pediatric	Endocrine	Society;	
•	 Asia	Pacific	Paediatric	Endocrine	Society	(APPES)
•	 Asia	Pacific	Initiative	on	Reproduction	(ASPIRE)
•	 Australasian	Paediatric	Endocrine	Group	(APEG)
•	 Australian	Diabetes	Society	(ADS)
•	 British	Fertility	Society	(BFS)
•	 Canadian	Society	of	Endocrinology	and	Metabolism	(CSEM)
•	 Dietitians	Association	Australia
•	 Endocrine	Society	(US	Endo)
•	 Endocrine	Society	Australia	(ESA)
•	 European	Society	of	Endocrinology	(ESE)
•	 European	Society	for	Paediatric	Endocrinology	(ESPE)
•	 Exercise	and	Sports	Science	Australia	(ESSA)
•	 Federation	of	Obstetric	and	Gynaecological	Societies	of	India	
(FOGSI)
•	 Fertility	Society	Australia	(FSA)
•	 International	Society	of	Endocrinology	(ISE)
•	 International	Federation	of	Fertility	Societies	(IFFS)
•	 International	Federation	of	Gynecology	and	Obstetrics	(FIGO)
•	 Italian	Society	of	Gynaecology	and	Obstetrics
•	 Japanese	Society	for	Paediatric	Endocrinology	(JSPE)
•	 Latin	American	Society	for	Paediatric	Endocrinology	(SLEP);	
•	 Nordic	Federation	of	Societies	of	Obstetrics	and	Gynaecology	
(NFOG)
•	 PCOS	Challenge
•	 PCOS	Society	of	India
•	 Paediatric	Endocrine	Society	(PES)
•	 Polycystic	Ovary	Association	Australia	(POSSA);	
•	 Royal	Australasian	College	of	Physicians	(RACP)
•	 Royal	Australian	College	of	General	Practitioners	(RACGP)
•	 Royal	 Australian	 and	New	 Zealand	 College	 of	 Obstetricians	
and	Gynaecologists	(RANZCOG)
•	 Royal	College	of	Obstetricians	and	Gynaecologists	(RCOG)
•	 South	African	Society	of	Gynaecology	and	Obstetrics	(SASOG)
•	 Verity	UK
•	 Victorian	 Assisted	 Reproductive	 Technology	 Association	
(VARTA)
Other	 relevant	 organizations	 are	welcome	 to	 partner	 in	 guideline	
translation	once	approved.
CONFLIC T OF INTERE S T
Disclosures	of	conflicts	of	interest	were	declared	at	the	outset	and	
updated	 throughout	 the	 guideline	 process,	 aligned	 with	 NHMRC	
guideline	 processes.	 Full	 details	 of	 conflicts	 declared	 across	 the	
guideline	development	groups	are	available	at	https://www.monash.
edu/medicine/sphpm/mchri/pcos/guideline	 in	 the	 Register	 of	 dis-
closures	 of	 interest.	 Of	 named	 authors,	 Dr	 Costello	 has	 declared	
shares	in	Virtus	Health	and	past	sponsorship	from	Merck	Serono	for	
conference	presentations.	Prof.	Laven	declared	grants	from	Ferring,	
Euroscreen	and	personal	fees	from	Ferring,	Euroscreen,	Danone	and	
Titus	Healthcare.	 Prof.	 Norman	 has	 declared	 a	minor	 shareholder	
interest	 in	an	IVF	unit.	The	remaining	authors	have	no	conflicts	of	
interest	to	declare.	The	guideline	was	peer	reviewed	by	special	inter-
est	groups	across	our	partner	and	collaborating	societies	and	con-
sumer	organizations,	was	 independently	assessed	against	AGREEII	
criteria,	and	underwent	methodological	 review.	This	guideline	was	
approved	by	all	members	of	the	guideline	development	groups	and	
was	submitted	for	final	approval	by	the	NHMRC.
AUTHOR ROLE S
Professor	 Teede,	 Professor	 Norman	 and	 all	 listed	 authors,	 were	
members	of	the	project	board,	and	coordinated	GDG	activities	from	
prioritizing	clinical	questions,	providing	clinical	 input	 into	evidence	
     |  17TEEDE ET al.
synthesis,	chairing	the	GDG	process	and	GRADE	framework	appli-
cation,	finalizing	recommendations,	responding	to	feedback	and	en-
dorsing	the	guideline.	Helena	Teede	was	the	guideline	development	
and	translation	lead	and	engaged	with	all	GDG	meetings,	overseeing	
the	process.	Joop	Laven,	Anuja	Dokras,	Lisa	Moran,	Terhi	Piltonen	
and	Michael	Costello	chaired	the	GDGs.	Marie	Misso	led	the	guide-
line	development	and	evidence	synthesis	processes.	Robert	Norman	
was	the	PCOS	Centre	for	Research	Excellence	co-	director,	the	dep-
uty	chair	of	 the	 International	advisory	board	and	the	deputy	chair	
of	 two	GDG’s.	 All	 other	 authors,	 were	 actively	 engaged	 as	 GDG,	
consumer,	 translation,	or	 international	advisory	board	members	or	
members	of	 the	evidence	 synthesis	 and	 translation	 team,	 contrib-
uted	 to	 the	 manuscript,	 prioritizing	 clinical	 questions,	 discussing	
recommendations	until	voting	and	consensus,	responses	to	external	
peer	 review	and	 approval	 of	 the	 final	 recommendations	 across	 all	
GDGs.
R E FE R E N C E S
	 1.	 Teede	H,	Deeks	A,	Moran	L.	Polycystic	ovary	syndrome:	a	complex	
condition	 with	 psychological,	 reproductive	 and	 metabolic	 man-
ifestations	 that	 impacts	 on	 health	 across	 the	 lifespan.	BMC Med. 
2010;8:41.
	 2.	 Azziz	R,	Carmina	E,	Chen	Z,	et	al.	Polycystic	ovary	syndrome.	Nat 
Rev Dis Primers. 2016;2:16057.
	 3.	 Gibson-Helm	M,	Teede	H,	Dunaif	A,	Dokras	A.	Delayed	diagnosis	and	a	
lack	of	information	associated	with	dissatisfaction	in	women	with	poly-
cystic	ovary	syndrome.	J Clin Endocrinol Metab.	2017;102(2):604-612.
	 4.	 Dokras	 A,	 Saini	 S,	 Gibson-Helm	M,	 Schulkin	 J,	 Cooney	 L,	 Teede	
H.	Gaps	 in	knowledge	among	physicians	 regarding	diagnostic	cri-
teria	 and	management	 of	 polycystic	 ovary	 syndrome.	 Fertil Steril 
2017;107(6):1380-1386.e1.
	 5.	 Teede	H,	 Gibson-Helm	M,	Norman	 RJ,	 Boyle	 J.	 Polycystic	 ovary	
syndrome:	perceptions	and	attitudes	of	women	and	primary	health	
care	physicians	on	features	of	PCOS	and	renaming	the	syndrome.	J 
Clin Endocrinol Metab.	2014;99(1):E107-E111.
	 6.	 Balen	AH,	Morley	LC,	Misso	M,	et	al.	The	management	of	anovulatory	
infertility	 in	women	with	polycystic	ovary	syndrome:	an	analysis	of	
the	evidence	to	support	the	development	of	global	WHO	guidance.	
Hum Reprod Update.	2016;22(6):687-708.
	 7.	 Goodman	 NF,	 Cobin	 RH,	 Futterweit	 W,	 Glueck	 JS,	 Legro	 RS,	
Carmina	 E.	 American	 Association	 of	 Clinical	 Endocrinologists,	
American	 College	 or	 Endocrinology	 and	 Androgen	 Excess	 and	
PCOS	Society	Disease	State	Clinical	Review:	guide	to	the	best	prac-
tices	in	the	evalution	and	treatment	of	polycystic	ovary	syndrome.	
Endocr Pract.	2015;21(11):1291-1300.
	 8.	 Legro	 RS,	 Arslanian	 SA,	 Ehrmann	DA,	 et	 al.	 Diagnosis	 and	 treat-
ment	 of	 polycystic	 ovary	 syndrome:	 an	 Endocrine	 Society	 clin-
ical	 practice	 guideline.	 J Clin Endocrinol Metab.	 2013;98(12): 
4565-4592.
	 9.	 Conway	G,	Dewailly	D,	Diamanti-Kandarakis	E,	Escobar-Morreale	
HF,	Franks	S,	Gambineri	A.	The	polycystic	ovary	syndrome:	a	posi-
tion	statement	from	the	European	Society	of	Endocrinology.	Eur J 
Endocrinol.	2014;171(4):P1-P29.
	10.	 Teede	HJ,	Misso	ML,	Deeks	 AA,	 et	 al.	 Assessment	 and	manage-
ment	of	polycystic	ovary	syndrome:	summary	of	an	evidence-	based	
guideline.	Med J Aust.	2011;195(6):S65-S112.
	11.	 Misso	M,	Teede	H.	Evidence	based	guideline	 (EBG)	development:	
a	 practical	 guide,	 in	 knowledge	 transfer:	 practices,	 types	 and	
challenges.	 In:	 Ilic	 D,	 ed.	Knowledge Transfer: Practices, Types and 
Challenges.	New	York,	NY:	Nova	Publishers;	2012.
	12.	 Brouwers	 M,	 Kho	ME,	 Browman	 GP,	 et	 al.	 AGREE	 II:	 advancing	
guideline	development,	reporting	and	evaluation	in	health	care.	Can 
Med Assoc J.	2010;182(18):E839-E842.
	13.	 GRADE	Working	Group.	Grading	of	recommendations	assessment,	
development	 and	 evaluation	 (GRADE)	 guidelines.	 http://www.
gradeworkinggroup.org/.
	14.	 National	 Health	 and	 Medical	 Research	 Council.	 NHMRC Levels 
of Evidence and Grades for Recommendations for Developers of 
Guidelines.	Canberra,	ACT:	National	Health	and	Medical	Research	
Council;	2009.
	15.	 National	Health	and	Medical	Research	Council.	NHMRC Standards 
and Procedures for Externally Developed Guidelines.	Canberra,	ACT:	
Australian	Government;	2007.
How to cite this article:	Teede	HJ,	Misso	ML,	Costello	MF,	
et	al.;	On	behalf	of	the	International	PCOS	Network.	
Recommendations	from	the	international	evidence-	based	
guideline	for	the	assessment	and	management	of	polycystic	
ovary	syndrome.	Clin Endocrinol (Oxf). 2018;00:1–18.  
https://doi.org/10.1111/cen.13795
APPENDIX 
International PCOS Network
Marianne	Andersen,	Odense	University	Hospital,	Denmark
Ricardo	Azziz,	State	University	of	New	York	System	Administration,	
USA
Adam	Balen,	Leeds	Teaching	Hospitals,	UK
Estifanos	 Baye,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Jacqueline	 Boyle,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Leah	Brennan,	Australian	Catholic	University,	Australia
Frank	Broekmans,	University	Medical	Centre	Utrecht,	Netherlands
Preeti	Dabadghao,	Sanjay	Gandhi	Postgraduate	Institute	of	Medical	
Sciences,	India
Luigi	Devoto,	University	of	Chile,	Faculty	of	Medicine,	Chile
Didier	Dewailly,	University	of	Lille,	France
Linda	 Downes,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Bart	Fauser,	University	Medical	Center	Utrecht,	Netherlands
Stephen	Franks,	Imperial	College,	London,	UK
Rhonda	 M.	 Garad,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Melanie	Gibson-Helm,	Monash	University,	Australia
Cheryce	 Harrison,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Roger	Hart,	The	University	of	Western	Australia,	Australia
Rachel	Hawkes,	Verity,	UK
Angelica	Hirschberg,	Karolinska	Institutet,	Sweden
18  |     TEEDE ET al.
Kathleen	Hoeger,	University	of	Rochester,	USA
Femke	Hohmann,	Huisartsenpraktijk	Hohmann	&	De	Vet,	Rotterdam,	
Netherlands
Samantha	 Hutchison,	 Monash	 Health	 Centre	 for	 Research	
Implementation,	Australia
Anju	 Joham,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Louise	 Johnson,	 Victorian	 Assisted	 Reproductive	 Treatment	
Authority,	Australia
Cailin	Jordan,	Genea	Hollywood	Fertility,	Australia
Jayashri	 Kulkarni,	 Monash	 Alfred	 Psychiatry	 Research	 Centre,	
Australia
Richard	S.	Legro,	Penn	State	College	of	Medicine,	Hershey,	PA,	USA
Rong	Li,	Peking	University	Third	Hospital,	China
Marla	Lujan,	Cornell	University,	USA
Jaideep	Malhotra,	Rainbow	Hospital,	India
Darren	Mansfield,	Monash	University	and	Monash	Health,	Australia
Kate	Marsh,	Northside	Nutrition	&	Dietetics,	Australia
Veryan	McAllister,	Polycystic	Ovary	Syndrome	Association	Australia,	
Australia
Edgar	 Mocanu,	 Royal	 College	 of	 Surgeons,	 Rotunda	 Hospital,	
Dublin	1,	Ireland
Ben	W.	Mol,	Monash	University,	Australia
Ernest	Ng,	Department	of	Obstetrics	&	Gynaecology,	The	University	
of	Hong	Kong,	Hong	Kong
Sharon	Oberfield,	Columbia	University	Medical	Center,	USA
Sasha	Ottey,	The	PCOS	Challenge:	The	National	Polycystic	Ovary	
Syndrome	Association,	USA
Alexia	Peña,	The	Robinson	Research	 Institute	 at	 the	University	of	
Adelaide,	Australia
Jie	Qiao,	Peking	University	Third	Hospital,	China
Leanne	Redman,	Pennington	Biomedical	Research	Center,	USA
Raymond	 Rodgers,	 The	 Robinson	 Research	 Institute	 at	 the	
University	of	Adelaide,	Australia
Luk	Rombauts,	Department	of	Obstetrics	and	Gynecology,	Monash	
University,	Australia
Daniela	 Romualdi,	 Fondazione	 Policlinico	 Universitario	 Agostino	
Gemelli,	Rome
Duru	Shah,	Gynaecworld,	India
Jane	Speight,	Deakin	University,	Australia
Poli	Mara	Spritzer,	Federal	University	of	Rio	Grande	Do	Sul,	Brazil
Elisabet	Stener-Victorin,	Karolinska	Institutet,	Sweden
Nigel	Stepto,	Victoria	University,	Australia
Juha	 S.	 Tapanainen,	 University	 of	 Helsinki,	 Helsinki	 University	
Hospital,	Finland
Eliza	 C.	 Tassone,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Shakila	Thangaratinam,	BARC	(Barts	Research	Centre	for	Women’s	
Health)	Barts	and	the	London	School	of	Medicine	and	Dentistry,	
Queen	Mary	University	of	London,	UK
Mala	Thondan,	Harp	Family	Medical	Centre,	Australia
Chii-Ruey	Tzeng,	Taipei	Medical	University	Hospital,	Taiwan
Zephne	van	der	Spuy,	University	of	Cape	Town,	South	Africa
Eszter	 Vanky,	 Department	 of	 Clinical	 and	 Molecular	 Medicine,	
Norwegian	University	of	Science	and	Technology,	Norway
Maria	 Vogiatzi,	 Children’s	 Hospital	 of	 Philadelphia,	 University	 of	
Pennsylvania,	USA
Angela	 Wan,	 Monash	 Centre	 for	 Health	 Research	 and	
Implementation,	Australia
Chandrika	Wijeyaratne,	Department	of	Obstetrics	and	Gynaecology,	
Faculty	of	Medicine,	University	of	Colombo,	Sri	Lanka
Selma	Witchel,	Children’s	Hospital	of	Pittsburgh	of	UPMC,	University	
of	Pittsburgh,	USA
Jane	Woolcock,	Women’s	and	Children’s	Hospital	Adelaide,	Australia
Bulent	O.	Yildiz,	Hacettepe	University	School	of	Medicine,	Ankara,	
Turkey
